AstraZeneca Presents Post-Hoc Data from P-III (NIAGARA) Trial of Imfinzi in Muscle-Invasive Bladder Cancer Patients regardless of Complete Pathology Response at ASCO GU 2025
Shots:
- The P-III (NIAGARA) trial assessed Imfinzi (4 cycles + neoadj. CT; then 8 cycles alone) vs CT with surgery in MIBC pts ± pCR; ongoing regulatory review in the US, EU, Japan & other areas
- Trial met its 2EPs of improved MFS (75.1% vs 65.1%) & DSS (89.2% vs 82.2%) in ITT pts (N=1063) with median MFS & DSS not reached, reducing distant metastases/death risk by 33% & bladder cancer death risk by 31%, where 37.3% vs 27.5% pts achieved pCR
- In pCR pts (n=345; EFS: 92.1% vs 85.8% & OS: 95.5% vs 91.1%) & non-pCR pts (n=718; EFS: 53.3% vs 49.5% & OS: 74.1% vs 68.9%), the study showed reduced risk in disease worsening, recurrence, surgery failure, or death by 42% & 23%, plus reduced death risk by 28% & 16%, respectively, as of Apr 29, 2024
Ref: AstraZeneca | Image: AstraZeneca
Related News:- AstraZeneca Reports CHMP Positive Opinion for Imfinzi to Treat Limited-Stage Small Cell Lung Cancer (LS-SCLC)
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Ridhi is an avid secondary researcher who follows trends in the biopharmaceutical and healthcare sectors to curate engaging content for the global audience. She works as a news editor at PharmaShots and loves to read books and explore new destinations.
